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data on the use of rituximab suggest it should be considered 
as a potential initial therapy in the treatment of patients with 
primary MN.
Keywords Membranous glomerulonephritis · 
Immunosuppression · Renal diseases · Glomerulopathies
Introduction
Membranous nephropathy (MN) is the most common cause 
of nephrotic syndrome in Caucasian adults. Considering the 
incidence of the glomerulopathies in Italy, MN is relatively 
frequent, representing 44.1% of patients diagnosed with 
nephrotic syndrome [1].
Initial studies performed in rat models (Heymann’s 
nephritis) documented that subepithelial immune depos-
its were formed in situ in the basal surface of podocytes 
following the autoimmune targeting of megalin, a protein 
not expressed in human podocytes [2]. The first proof of 
concept that the same pathogenic mechanism may occur in 
humans came from Debiec et al. describing in situ formation 
of immune deposits in a neonate born to a mother deficient 
in neutral endopeptidase (NEP), a protein expressed in the 
podocytes [3]. During previous pregnancies, the mother 
developed antibodies against NEP, which crossed the pla-
centa and bound to the protein in the fetal podocytes, leading 
to the development of primary MN. However, these cases 
are extremely rare. A major breakthrough came when Beck 
et al. identified circulating autoantibodies against the M-type 
phospholipase  A2 receptor (antiPLA2R Abs) that are present 
in the serum of approximately 70% of patients with MN [4].
Subsequent studies by Tomas et al. identified new cir-
culating autoantibodies against thrombospondin Type-1 
domain-containing 7A (anti-THSD7A Abs) in 5–10% of 
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patients with MN who are anti-PLA2R negative [5]. As 
such, in approximately 80% of the cases an autoantibody 
can be identified and the disease is considered primary MN. 
In the majority of the remaining cases, an underlying cause 
such as drugs, infections, malignancies or systemic autoim-
mune disease can be identified and the disease is considered 
secondary MN [6]. Antibodies to not yet recognized podo-
cytes’ antigens are likely to account for the remaining cases 
of ‘idiopathic’ MN.
In this review, we summarize the prognosis and the sev-
eral lines of treatment proposed in the literature for primary 
MN.
Anti‑PLA2R antibodies as diagnostic tools
Among the blood tests currently available, the indirect 
immunofluorescence test (IIF) holds the best sensitivity 
for anti-PLA2R Abs; its semi-quantitative nature, how-
ever, makes it less useful in monitoring disease activity and 
response to immunosuppressive therapy. Enzyme-linked 
immunosorbent assay (ELISA) tests are less sensitive than 
IIF but are less time consuming and allow for accurate quan-
titation of the circulating anti-PLA2R Abs levels. On the 
other hand, the use of a high threshold for seropositivity in 
commercial ELISA tests (>14 RU/ml), may lead to consider 
low-titer samples falsely negative.
On renal biopsy the diagnosis of PLA2R related MN can 
be made by demonstrating PLA2R staining overlapping the 
granular pattern of immunoglobulin (Ig)G deposits (IgG4 
dominant). This “enhanced” pattern must be differentiated 
from the weak background positivity of the PLA2R Ag 
which can be detected in normal kidney. Approximately 30% 
of patients with PLA2R Ag positive deposits on renal biopsy 
may nave negative anti-PLA2R in the serum [7]. This sce-
nario can be explained by two different mechanisms. In the 
first one anti-PLA2R Abs negativity reflects an immunologic 
remission (spontaneous or induced by immunosuppressive 
therapy) that precedes immunodeposits clearance and clini-
cal remission. The second mechanism could be explained 
by a phenomenon called “kidney as a sink”: anti-PLA2R 
Abs are cleared from the blood by the bind to target antigens 
in podocyte and they become detectable in the blood only 
when their rate of production exceeds the buffering capacity 
of the kidney [8].
The positivity of either serology or histology defines 
PLA2R-associated MN. In the serum, a positive anti-PLA2R 
Abs titer is extremely specific for MN (almost 100%), since 
circulating antibodies have not been detected in healthy 
individuals or in the setting of other autoimmune disorders 
[9]. Accordingly, some authors proposed that kidney biopsy 
can be avoided in patients who are antiPLA2R Abs posi-
tive, have normal renal function and do not have evidence 
of secondary MN, e.g. hepatitis B/C, systemic lupus erythe-
matosus (SLE), malignancy, etc. [8–10]. In the case of nega-
tive serology for antiPLA2R Abs, however, a renal biopsy is 
mandatory to establish the diagnosis [11]. Of note, several 
cases of PLA2R- associated MN concomitant with hepati-
tis B, C, sarcoidosis and less frequently malignancies, have 
been reported [12–16]. It is unclear if MN is concomitant or 
secondary to the coexisting disease [8].
Similarly, recent evidence shows a prevalence of malig-
nancies of up to 20% among patients with THSDA7A-related 
MN, particularly endometrial and gallbladder carcinomas, 
suggesting the need for an aggressive screening for cancer 
when these antibodies are detected [17]. A semi-quantitative 
indirect immunofluorescence test has been recently devel-
oped to detect circulating THSDA7A antibodies [18]. Theo-
retically, if both circulating PLA2R antibodies and PLA2R 
antigens on IF microscopy are negative, and immune depos-
its appear IgG4 dominant, a THSD7A-related MN should 
be ruled out. However, there are some additional elements 
that may help to differentiate cancer- vs. non cancer-related 
MN [19].
Anti‑PLA2R antibodies level to monitor disease 
activity and predict prognosis in primary MN
The natural history of the disease is heterogeneous. Approxi-
mately 20–30% of patients will develop spontaneous com-
plete remission [20] and 30–40% of patients will progress 
to end-stage renal disease (ESRD) [8]. In the remaining 
patients mild to moderate proteinuria, with stable renal func-
tion, persists over time. Predicting disease progression is 
important in order to restrict immunosuppressive therapy to 
those patients with significant risk of progression to ESRD.
Traditionally, several factors have been suggested as pre-
dictors of poor prognosis for developing renal insufficiency 
in primary MN, including male gender, age >50 years, 
hypertension, histological markers, and proteinuria and 
creatinine at presentation [21]. Among these risk factors, 
persistent proteinuria, initial creatinine clearance and change 
in creatinine clearance over time have shown the best pre-
dictive value in identifying patients at increased risk of dis-
ease progression [22]. According to the Toronto Risk Score 
which has been validated in several countries three groups 
of risk were recognized:
1. a “low risk” group, defined by patients with normal 
serum creatinine/creatinine clearance and proteinu-
ria consistently ≤4 g/24 h over a 6-month observation 
period,
2. a “medium risk” group, defined by patients with nor-
mal and stable kidney function and with proteinuria 
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>4 ≤ 8 g/24 h over 6 months of observation (55% prob-
ability of developing ESRD within 10 years),
3. a “high risk” group, defined as patients with persistent 
proteinuria >8 g/24 h, independent of the degree of kid-
ney function impairment (66–80% probability of pro-
gression to ESRD in 10 years).
The Toronto Risk Score predicts with an 80–90% accu-
racy the risk of progression of patients affected by pri-
mary MN. However, a long period of observation (at least 
6 months) is needed to calculate the risk score with a pro-
longed delay for the start of treatment [14, 23].
Since the discovery of anti-PLA2R Abs, an increasing 
body of evidence supports the quantification of these autoan-
tibodies as a reliable tool to predict spontaneous remission, 
disease progression and monitor the response to treatment. 
The occurrence of spontaneous remission is more common 
in patients with low antibody titers compared to those with 
high antibody titers [24, 25]. Anti-PLA2R Abs levels may 
predict progression from sub-nephrotic proteinuria to full 
nephrotic syndrome [26]. High titers of anti-PLA2R anti-
bodies have also been associated with the rate of relapses, 
lower response to immunosuppressive therapy and longer 
time to remission [27]. Furthermore, high antibody levels 
are associated with high rapid loss of kidney function [28].
The evolution of anti-PLA2R Abs levels in response to 
immunosuppression reliably predicts outcomes. Relapse rate 
also correlates with the level of antibodies at the time of clin-
ical remission, with patients who become anti-PLA2R Abs 
negative having lower relapse rates than patients who remain 
anti-PLA2R Abs positive at the end of immunosuppression.
Hosfra et al. analyzed a cohort of 82 patients with pri-
mary MN, and showed an inverse correlation between anti-
PLA2R Abs levels and rate of spontaneous remission (38 
vs. 4% in the lowest and highest tertiles, respectively) [29]. 
High anti-PLA2R Abs levels can predict a more rapid loss of 
renal function [30]. The titer of autoantibodies was directly 
correlated with proteinuria and serum creatinine, strong pre-
dictors of disease activity [24].
In patients treated with rituximab, Beck et al. demon-
strated that 88% of patients with a drop in antibody levels 
developed complete or partial remission by 24 months vs. 
33% for those with no significant immunologic response to 
rituximab treatment [27]. Of note, decline in anti-PLA2R 
almost always preceded the decline in proteinuria by 
months. Subsequent studies showed that antibody levels 
decrease independently of the type of immunosuppressive 
therapy [28].
In 2015 Ruggenenti et  al. published a series of 132 
patients with primary MN treated with rituximab, show-
ing that all 25 complete remissions were preceded by anti-
PLA2R Abs depletion, and lower baseline anti-PLA2R 
Abs level strongly predicted remission [31]. As initially 
demonstrated by Beck et al., a 50% reduction of anti-PLA2R 
Abs titer anticipated an equivalent reduction of proteinu-
ria by 10 months and re-emergence of circulating antibod-
ies predicted relapses of the disease [31]. Furthermore, a 
study performed by Bech et al. included 48 patients with 
primary MN and high risk of progression treated with 
cyclophosphamide or mycophenolate mofetil in combina-
tion with corticosteroids for 12 months, with 33 patients 
positive for anti-PLA2R Abs. Although in this study the 
levels of autoantibodies at baseline did not predict the initial 
response, the anti-PLA2R Abs titer at the end of the therapy 
predicted long-term outcomes. After 5 years of follow-up, 
14 of 24 patients with a negative titer of autoantibodies at 
the end of treatment were in persistent remission compared 
to 0 of 9 patients with persistent circulating anti-PLA2R 
Abs [27].
The prognosis for patients with primary MN and no cir-
culating antibodies seems to be less clear; recently Hoxha 
et al. described a high proportion of spontaneous remission 
in anti-PLA2R Abs and anti-THSD7A Abs-negative patients 
[25]. Therefore, maximizing support therapy may be a rea-
sonable initial approach in these cases. Serial anti-PLA2R 
Abs assessment is required in those patients with positive 
PLA2R Ag staining in renal biopsy, who are seronegative 
for anti-PLA2R Abs.
Supportive therapy
Supportive therapy involves restricting dietary sodium to 
less than 2 g/day, restricting protein intake (0.8–1 g/kg/day), 
and controlling blood pressure (blood pressure targeted to 
125/75 mmHg), hyperlipidemia, and edema. This approach 
is recommended by KDIGO guidelines for all patients with 
MN and nephrotic syndrome [32].
Angiotensin-converting enzyme inhibitors (ACEi) or 
angiotensin receptor blockers (ARBs) should be the first 
line of therapy in all cases, due to their antiproteinuric 
effect. However, it should be considered that in patients with 
primary MN their antiproteinuric effect is modest (<30% 
decrease from baseline), in part because the majority of 
these patients are not hypertensive. Moreover, the antipro-
teinuric effect has been mainly observed in those patients 
with a lower degree of proteinuria [20] and use of ACEi or 
ARB therapy has not shown to be related to prognosis in 
patients with primary MN [33]. Dual blockade of the renin-
angiotensin system can be used in patients who do not have 
diabetes or significant cardiovascular disease and can toler-
ate it.
In addition, supportive therapy must be directed to 
improve hyperlipidemia and lessen the risk of thromboem-
bolism in patients with primary MN.
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The effect of statins on cardiovascular disease in patients 
with primary MN has not been demonstrated in clinical tri-
als. However, most clinicians consider hyperlipidemia as a 
significant risk factor for cardiovascular disease in patients 
with nephrotic syndrome.
The use of anticoagulant therapy should be considered in 
cases of primary MN with a high risk for thrombotic events 
(in particular: proteinuria >10 g/day, positive family history, 
previous thrombotic events, serum albumin less than 2 g/
dl, obesity or physical inactivity). A recent study evaluating 
898 patients with primary MN showed that venous throm-
boembolic events occurred in approximately 7% of patients, 
with an incidence rate significantly higher than for other 
causes of nephrotic syndrome. A serum albumin level less 
than 2.8 g/dl was the only independent predictor of venous 
thromboembolism [34].
Immunosuppressive therapy
We will now review the most commonly used therapeu-
tic approaches in clinical practice (Table 1) as well as the 
degree of evidence supporting such practices (Table 2).
Corticosteroid monotherapy
In 1979, the first randomized controlled trial in patients with 
primary MN showed that a short course of high-dose pred-
nisone monotherapy (125 mg every other day for 8 weeks) 
was associated with a reduced rate of deterioration in renal 
function when compared to placebo [35]. Nevertheless, this 
study was criticized because of the really poor rate of renal 
survival in the control group. Two subsequent studies failed 
to show a beneficial effect of corticosteroid monotherapy on 
survival, proteinuria and renal function in primary MN [36, 
37]. Moreover, meta-analyses did not demonstrate a benefit 
on renal survival/death and complete remission rates [38, 
39]. As such, the KDIGO guidelines do not recommend cor-
ticosteroid monotherapy in patients with primary MN [32].
Alkylating agents
The combination of corticosteroids and cyclophosphamide 
or chlorambucil has improved substantially the prognosis 
of patients with primary MN (Table 2) [38–40]. In 1984, 
Ponticelli’s group demonstrated the efficacy of a 6-month 
schedule of alternate monthly courses of glucocorticoids 
and chlorambucil in patients with primary MN, nephrotic 
syndrome and normal renal function. During a mean fol-
low-up of 31 months, the intervention group showed a 72% 
rate of complete or partial remission compared to 30% in 
the placebo group [41]. A 10-year follow-up revealed a 
higher rate of remission and dialysis-free survival in the 
treated group than placebo group (62 vs. 33 and 92 vs. 60%, 
respectively) [42]. In a subsequent study, chlorambucil was 
compared with cyclophosphamide (CYC) as an alkylating 
agent. Patients assigned to chlorambucil treatment received 
steroids on months 1, 3 and 5 (methylprednisolone 1 g iv 
on three consecutive days followed by prednisone 0.4 mg/
kg/day for 27 days) and oral chlorambucil on months 2, 4 
and 6 (0.2 mg/kg/day); in the CYC group, chlorambucil was 
substituted by oral CYC (2.5 mg/kg/day). The two groups 
did not show significant differences in remission rate (82% 
in the chlorambucil group and 93% in the CYC group after 
1-year follow-up) and relapse rate (30.5 vs. 25% after 30 
months of follow-up). The safety profile was more favora-
ble in the CYC group, with lesser patients who had to stop 
treatment because of side effects (5% in CYC vs. 14% in the 
chlorambucil group) [43].
Similar results were found by Jha et al. in an open-label, 
randomized study comparing treatment with a CYC-based 
Ponticelli regimen (methylprednisolone 1 g/day for three 
consecutive days followed by oral prednisolone 0.5 mg/kg/
day for 27 days on months 1, 3 and 5 and oral cyclophospha-
mide at 2 mg/kg/day on months 2, 4 and 6) versus support-
ive therapy, in adults with nephrotic syndrome and biopsy-
proven primary MN. This study confirmed the efficacy of 
cytotoxic therapy in inducing remission (72 vs. 34% in the 
control group), leading to a superior long-term renal survival 
(89 vs. 65%, after a mean follow-up of 11 years) [44].
More recently, the UK Membranous trial attempted to 
identify the best approach for patients considered at high risk 
of progression (defined as a decline of estimated glomerular 
filtration rate (eGFR) ≥20% during the previous 2 years). 
A cohort of 108 patients was randomized to treatment with 
cyclosporine A (CSA) monotherapy (12 months), chloram-
bucil-based Ponticelli schedule (6 months) or supportive 
therapy alone. The risk of a further 20% decline in eGFR 
was significantly lower in the chlorambucil group, but not 
in the CSA group compared with supportive therapy alone. 
The rate of progression in the chlorambucil group (58%) was 
greater than in other randomized controlled trials (5–8%), 
raising concerns about the lesser effectiveness of late treat-
ment in primary MN. The surrogate renal endpoint (20% 
reduction in eGFR) could be inappropriate, since several 
factors such as diuretic use or lowering of blood pressure 
might all contribute to slight changes in serum creatinine 
levels [45].
Although CYC and chlorambucil are equally effective 
in inducing remission, CYC has a better tolerability profile 
and is associated with less short and long-term side effects, 
in particular bone marrow suppression and hematological 
malignancies [43, 46]. For practical purpose, chlorambucil 
is no longer used as an alkylating agent in the treatment of 
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primary MN. However, serious adverse events secondary 
to CYC exposure have been widely reported (in particular 
following cumulative doses superior to 36 g), such as malig-
nancies, infertility and severe bone marrow suppression. In 
a cohort of 293 patients with granulomatosis with poly-
angiitis, a cumulative CYC dose over 36 g was associated 
with an increased risk of cancer (bladder cancer and acute 
myeloid leukemia). Moreover, risk of gonadic toxicity has 
been reported with cumulative doses of 10–15 g in female 
patients and 200–250 mg/kg in male patients [6]. Taking into 
account that a patient of 80 kg treated with a course of CYC 
2.5 mg/kg per day for 3 months would receive a cumulative 
dose of 18 g, CYC appears of limited utility in relapse treat-
ment and its choice as first-line treatment should take into 
consideration the high risk of infertility [6].
Several cases of Pneumocystis jirovecii pneumonia have 
been reported in patients exposed to alkylating agents; there-
fore, prophylactic treatment with trimethoprim-sulfamethox-
azole is recommended [47].
Calcineurin inhibitors (CNI)
CSA and tacrolimus (TAC) can be used to induce remission 
in patients affected with primary MN with preserved renal 
function (creatinine clearance >60 ml/min); these drugs 
are not mutually exclusive, and resistance to CSA does not 
mean resistance to TAC or vice versa [45]. According to the 
KDIGO guidelines (2012), these drugs are considered an 
alternative therapy when alkylating agents combined with 
corticosteroids are contraindicated or refused by the patient 
[32].
Support for CNI use comes from two randomized con-
trolled trials (RCTs) from Canada. The first study involved 
patients diagnosed with progressive primary MN, identified 
by an absolute decrease in creatinine clearance ≥8 ml/min 
and persistent nephrotic range proteinuria after 12 months of 
supportive therapy. The patients were randomly assigned to 
CSA (initial dose: 3.5 mg/kg/day, desired 12-h trough level 
between 110 and 170 μg/l for 12 months) or placebo. After 
12 months, the CSA group showed a greater improvement in 
creatinine clearance slope and proteinuria; these results were 
sustained in 75% of CSA patients [48]. A subsequent study 
compared CSA (3.5 mg/kg/day adjusted according to serum 
levels between 125 and 225 μg/l for 6 months) plus low dose 
steroids (prednisone 0.15 mg/kg/day up to a maximum daily 
dose of 15 mg) to low dose steroids alone in 51 patients with 
corticosteroid-resistant disease. After 26 weeks of treatment, 
the CSA arm achieved 75% of remissions compared to 22% 
in the placebo arm. The relatively short course of CSA was 
associated with a high rate of relapses of 43% at week 52 
and 48% at week 78 [49].
Current KDIGO guidelines recommend that in patients 
who achieved remission, CSA treatment should be continued 
for at least 12 months before considering discontinuation 
[32].
TAC was introduced after a successful clinical trial 
from Spain, which expanded the experience inherited from 
renal transplantation. A total of 48 patients were randomly 
assigned to receive either supportive therapy and TAC mon-
otherapy (0.05 mg/kg/day for 12 months and then tapered 
over 6 months, with a desired trough level of 3–5 ng/ml) 
or supportive therapy alone. After 18 months, 76% of the 
patients treated with TAC achieved complete or partial 
remission vs. 30% in the control group. As observed in 
CSA, 47% of patients had a relapse within 18 months of 
TAC withdrawal (mean time to relapse 4.2 months) [50]. 
The remission rates of the Spanish study were recently con-
firmed in a multicenter retrospective study, where primary 
MN patients (34% of whom previously treated with other 
regimens) achieved 84% of complete or partial remission; as 
previously described, 44% of the responders relapsed after 
the treatment was tapered [51].
Hypertension and nephrotoxicity are the major side 
effects seen in patients treated with CNI. This is particularly 
important since many responders will become CNI depend-
ent. Worsening in renal function in these patients may be 
managed by decreasing the daily dose of CNI [52].
Mycophenolate mofetil (MMF)
MMF is a potent, selective and reversible inhibitor of ino-
sine monophosphate dehydrogenase, a crucial enzyme of the 
de novo pathway of guanosine nucleotide synthesis. T- and 
B-lymphocytes are highly dependent on this pathway and 
its inhibition results in a significant cytostatic effect. This 
immunosuppressive agent presents a better safety profile 
compared to CYC and is widely used for the treatment of 
glomerular diseases, in particular lupus nephritis.
Initials reports were published about the clinical efficacy 
of MMF monotherapy for patients with primary MN resist-
ant to CNI and cytotoxic agents. A case series described 16 
patients resistant to multiple therapeutic regimens who were 
treated with an initial dose range from 500 to 2000 mg/day 
for a mean 8 months. Partial or complete remission occurred 
in eight patients (50%) [53]. A subsequent randomized con-
trolled trial involved 19 patients-naive treated with MMF 
monotherapy (2 g per day) for 12 months and 17 patients 
with conservative therapy. After 1 year of follow-up, no dif-
ferences were found between groups in terms of remission 
rate (37% in the intervention group vs. 41 in the control 
group) and proteinuria [54].
A Dutch study compared 32 patients treated with MMF 
(1 g twice a day) with 32 historic controls treated with CYC 
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(1.5 mg/kg/day) for 12 months; both groups also received 
pulses of methylprednisolone (3 g iv on months 1, 3 and 5) 
and alternate-day prednisone (0.5 mg/kg every other day). 
The median follow-up of the MMF group was 23 months. 
MMF combined with high-dose steroids was as effective as 
CYC in increasing serum albumin and decreasing proteinu-
ria through a period of 12 months, with a remission rate of 
66% in the MMF group vs. 72% in the CYC group. However, 
MMF-treated patients showed a higher rate of primary non 
response and more frequently experienced relapses 2 years 
after the end of treatment (70 vs. 20% in the CYC group) 
[55].
For these reasons, although the combination of MMF 
with a high dose of corticosteroids appears effective, 
KDIGO guidelines do not recommend MMF as the first line 
of treatment for patients with primary MN [32].
Azathioprine (AZA)
AZA was considered as a low side-effect alternative to 
alkylating agents. Some case series described the efficacy 
of an association of AZA and corticosteroids [56], but a pro-
spective observational study showed no benefits in rates of 
remission of proteinuria (51 vs. 58%, p = NS) and progres-
sion to ESRD (21 vs. 18%, p = NS) in patients treated with 
corticosteroids plus AZA compared to the control group in 
the long-term period (10 years) [57].
Rituximab (RTX)
RTX is a chimeric monoclonal antibody directed against 
the membrane protein CD20 expressed on the surface of 
mature B-lymphocytes, but not on hematopoietic stem cells 
and plasma cells. Since it has been approved in 1997 by the 
US Food and Drug Administration (FDA) for the treatment 
of non-Hodgkin’s lymphoma, the use of RTX has expanded 
into the field of immune-mediated glomerular disease, such 
as anti-neutrophil cytoplasmic antibodies-associated vasculi-
tis, lupus nephritis, minimal change disease, focal segmental 
glomerulosclerosis and primary MN [58].
The first study of RTX in primary MN reported a case 
series of 8 patients treated with the ‘lymphoma protocol’ 
(375 mg/m2 weekly for four doses). Sixteen weeks after 
the end of the treatment, two patients achieved complete 
remission and three patients partial remission [59]. After 
12 months of follow up, all five patients maintained remis-
sion and RTX revealed also an antiproteinuric effect in the 
remaining three patients, with a reduction of more than 40% 
compared to baseline proteinuria. No major side effects were 
reported, only three adverse events with the first infusion 
[60].
Afterwards, in an open-label pilot trial from Mayo Clinic, 
15 patients with primary MN were treated with 1 g of RTX 
at time 0 and repeated after 15 days for a total of two doses 
(‘rheumatoid arthritis’ protocol). After a follow-up of 6 
months, proteinuria decreased by 50%; at 1-year follow-up, 
two and six patients achieved complete and partial remis-
sion, respectively [61]. A subsequent study was performed, 
by the same group, using the lymphoma protocol in a cohort 
of 20 patients. After 1 year, the remission rate was 50%, 
increasing to 80% after 2 years, with four patients in com-
plete remission and 12 in partial remission; moreover, only 
one patient (5%) relapsed [62]. These studies showed a more 
effective depletion of CD20+ cells with the lymphoma regi-
men, but no differences in the effectiveness were demon-
strated. Moreover, in both studies, no relationship was found 
between the response and number of B-cells in the blood, 
CD20+ cells in renal tissue, degree of tubulointerstitial 
fibrosis, starting proteinuria or creatinine values [62].
A subsequent case series from Mario Negri’s group 
described RTX treatment in 100 patients with primary MN 
and nephrotic syndrome resistant to inhibitors of the renin-
angiotensin system or other immunosuppressive regimens 
(32%). The majority received only a single dose of RTX 
(according a B-cell titrated protocol); complete or partial 
remission was achieved in 65% of cases and proteinuria 
decreased over time from 9.1 to 4, 2 and 1.5 g/day at 1, 2 and 
3 years of follow-up, respectively [63]. Similarly, another 
case series of 12 patients with primary MN resistant to other 
immunosuppressive regimens (CSA or alkylating agents) 
underwent a RTX-lymphoma regimen with 12 months of 
follow-up. Complete and partial remission was achieved in 
21.4 and 50%, respectively [64]. No treatment-related seri-
ous adverse events were reported in either study.
More recently, a multicenter randomized trial of RTX 
performed by the GEMRITUX study group compared RTX 
(375 mg/m2, day 1 and 8) plus conservative therapy vs. con-
servative therapy alone. At 6 months, the study group did 
not find any difference in complete plus partial remission 
rates (35.1% in RTX group vs. 21.1% in the conservative 
therapy group). However, post-RCT observation after a 
median follow-up of 17 months revealed a higher remission 
rate in the RTX group (64.9%) than the conservative group 
(34.2%) [65].
Although RTX and alkylating agents have not been 
directly compared in a single RCT, RTX has shown an excel-
lent side-effect profile. The most common adverse effects are 
infusion related [61, 63] and can be significantly reduced by 
pretreatment with acetaminophen, methylprednisolone and 
antihistamine. As for alkylating agents, pneumocystis proph-
ylaxis should be considered. However, RTX is not devoid of 
potential severe side effects. In 2006, the FDA issued a Drug 
Safety newsletter regarding two cases of fatal progressive 
multifocal leukoencephalopathy (PML) in patients affected 
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with non-Hodgkin’s lymphoma who had been treated with 
RTX [66]. These patients received high-dose chemotherapy 
before or in association with RTX. Other cases related to 
PML have been reported in patients with hematological 
disorders or rheumatologic disorders (including SLE) [67]. 
Remarkably, to the best of our knowledge, no such case has 
been reported in patients treated with RTX monotherapy.
Fatal fulminating hepatitis due to reactivation of hepatitis 
B virus after RTX has been reported [68]. As such, treatment 
with RTX in patients with hepatitis B should be carefully 
evaluated and requires the use of antiviral prophylaxis [69].
Data about risk of malignancies in RTX-treated patients 
mainly come from the experience in treatment of hemato-
logic malignancies. Two different studies showed that RTX-
containing regimens were not associated to an increased risk 
of malignancy compared to non-RTX containing regimens 
in B-cell non Hodgkin lymphoma [70, 71]. An increase in 
solid tumors were, instead, reported when RTX was used 
with high-dose chemotherapy (HDT) and autologous stem 
cell transplantation [72]. However, it should be stressed that 
long-term data on risk for malignancies are not available for 
RTX monotherapy.
Considering the toxicity of the alkylating agents, particu-
larly in patients with relapsing disease, the available evi-
dence suggests that RTX could be considered as a first line 
of therapy in primary MN. Unfortunately, RTX is expensive: 
the cost of a ‘rheumatoid arthritis schedule’ is around €8268. 
On the other hand, a single dose of 375 mg/m2 (as envis-
aged in the B-cell driven protocol) costs €3200 for an aver-
age 70 kg patient [73, 74] compared to a cost of €450 for a 
corticosteroid-based regimen with CYC for 6 months at the 
currently recommended doses [74]. However, if we consider 
the low rate of moderate to severe side effects (as discussed 
above) as well as the low rate of relapse, the cost-gap of 
RTX-based regimens appears to narrow when compared 
with the standard of care. In fact, hospitalization in Italy 
costs around € 800/day (excluding therapeutic interventions) 
[75]. These considerations closely match those with other 
experiences in immunology [75, 76] and hematology [77].
Three randomized controlled trials with RTX are 
ongoing:
1. The MEmbranous Nephropathy Trial Of Rituximab 
(MENTOR) study (NCT01180036) is an open-label 
RCT designed to evaluate RTX (1000 mg, iv day 1 and 
15, repeated after 6 months if the reduction of proteinu-
ria is >25%) versus CSA (3.5–5 mg/kg/day; target lev-
els 125–175 ng/dl) for 6 months, and continued for an 
additional 6 months if proteinuria reduction is >25%, in 
maintenance of remission at 24 months from randomiza-
tion [78]. Results are anticipated in late 2017.
2. The Sequential treatment with Tacrolimus–Rituximab 
vs. steroids plus cyclophosphamide in patients with 
primary MEmbranous Nephropathy (STARMEN) 
trial (NCT01955187) is now in the recruitment phase 
and will compare a TAC-RXT treatment (experimen-
tal group) with Ponticelli’s schedule (control group). 
The experimental group will receive TAC for 9 months 
(initial dose of 0.05 mg/kg/day, adjusted to achieve 
blood trough levels between 5–7 ng/ml, maintained for 
6 months and then progressively tapered) plus RTX 1 g 
iv at month 6. The rates of remission, relapse, preserva-
tion of renal function and adverse effects will be evalu-
ated in a 2-year follow-up [79].
3. The RI-CYCLO trial (NCT03018535) is recruiting 
patients from Italian facilities to provide a head-to-head 
comparison between RTX (1000 mg, day 1 and 15) and 
Ponticelli’s schedule (month 1, 3 and 5: 1000 mg iv 
methylprednisolone daily × 3 followed by prednisone 
0.5/mg/kg/day; month 2, 4 and 6: oral cyclophospha-
mide 2.0 mg/kg/day), since RCTs are still missing.
Adrenocorticotropic hormone (ACTH)
ACTH is physiologically produced by the pituitary gland 
and stimulates the production of endogenous glucocorti-
coids and indirectly activates the melanocortin receptors, 
which play a role in various physiologic functions, including 
melanin synthesis, immunomodulation, anti-inflammation, 
lipolysis stimulation and modulation of exocrine function 
[80]. Basic research in rodents identified gene expression of 
these receptors in podocytes, glomerular endothelial cells, 
mesangial cells and tubular epithelial cells. In animal models 
of primary MN treated with a specific melanocortin receptor 
agonist, it significantly reduced proteinuria, oxidative stress 
and improved podocyte morphology [81].
The first pilot study evaluated 14 patients with primary 
MN who were treated with synacthen, a synthetic version of 
ACTH. Patients received synacthen starting at 1 mg intra-
muscularly every other week with the dose increased to 
1 mg intramuscularly 3 times/week for 8 weeks. There was 
a 90% reduction in proteinuria at the end of the treatment. 
A subgroup of five patients, who were severely nephrotic 
and non-responsive to previous therapies, underwent a total 
treatment period of 12 months: 18 months after the end of 
treatment, all of them were still in remission [82]. These data 
were confirmed in an Italian RCT showing no differences 
between patients treated with cyclic steroids (methylpredni-
solone 1 g iv on three consecutive days, then 0.4 mg/kg/day 
orally for 27 days on month 1, 3 and 5) + CYC (2.5 mg/kg/
day orally on month 2,4 and 6) versus synacthen (initially 
1 mg intramuscularly every other week then increased up to 
1 mg twice weekly for a total treatment period of 1 year), 
with remission rates of 94 and 88%, respectively [83]. A sec-
ond open-label, prospective study demonstrated beneficial 
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effects of natural ACTH (ACTHar gel 80 IU subcutaneously 
twice weekly) in resistant glomerular diseases, including five 
patients with primary MN and significant reduction in renal 
function (eGFR < 45 ml/min) who were resistant to other 
immunosuppressive agents: three of these patients achieved 
immunologic remission with a negative anti-PLA2R Abs 
titer after 4 months of treatment, with a clinical partial 
remission occurring in two of them [84].
In 2014, Hladunewich et  al. published a prospective 
open label study in 20 patients with primary MN and 
eGFR > 40 ml/min, receiving subcutaneous ACTHar gel at 
a dose of 40 or 80 IU twice weekly for a total of 12 weeks. 
Results showed an improvement in proteinuria (decrease 
≥50% from baseline) in 65% of patients after 12 months 
of follow-up, with two complete remissions and ten partial 
remissions. An improvement in serum albumin and lipid 
profile was also demonstrated. Lower doses of ACTH (40 IU 
twice weekly) were associated with a poor response with 
no significant improvement in proteinuria after 12 weeks 
of treatment. Five patients who were initially treated with 
40 IU twice weekly were continued on ACTHar gel 80 IU 
twice weekly for an additional 12 weeks. Interestingly, these 
patients showed a significant improvement in proteinuria 
after 12 months of follow-up; these results suggest that the 
effect of ACTH is dose dependent. The drug was well tol-
erated and safe [85]. The most frequent side effects were 
weight gain and hyperglycemia [83, 84].
Novel therapeutic perspectives
Ofatumumab is an anti-CD20 monoclonal antibody, which 
differs from RTX in terms of the different target-epitope: it 
showed efficacy in the treatment of B-cell lymphomas and 
other hematological malignancies which had previously 
not responded to RTX [86, 87]. Ruggenenti et al. recently 
described two cases of clinical remission of primary MN 
in patients who developed primary or secondary resistance 
to RTX [74]; these patients belong to a larger unpublished 
cohort of nephrotic patients with normal renal function suc-
cessfully treated with ofatumumab as rescue therapy after 
failure of RTX. Resistance to RTX in these cases, is likely 
due to a change in the CD20 antigen conformation, which 
prevents B cell-RTX binding and the consequent B-cell 
depletion [74].
The B lymphocyte stimulator protein (BLyS, also known 
as BAFF) is a soluble member of the tumor necrosis fac-
tor family, which plays a fundamental role in B lymphocyte 
activation and differentiation [88]. Belimumab, a monoclo-
nal antibody directed against BLyS, has been tested in 14 
proteinuric patients with antiPLA2R-positive primary MN 
from six different centers in UK [89]. The treatment protocol 
consisted in 10 mg/kg iv belimumab every 4 weeks for at 
least 28 weeks up to week 100 (frequency increased to every 
2 weeks if urine protein-creatinine ratio >1000 mg/mmol) 
and supportive therapy. After 12 weeks, the anti-PLA2R 
antibody titer showed a significant reduction (−46%) and 
the urine protein-creatinine ratio decreased by 38% after 
38 weeks. BLyS inhibition seems to induce apoptosis and 
depletion of autoreactive B cells: this mechanism of action 
has been proposed as the main cause of the slower effect of 
belimumab with respect to rituximab, which likely induces 
complement-mediated cytolysis of CD20-positive cells [74].
There is also increasing interest in the use of anti-plasma 
cell agents as rescue treatment in resistant primary MN. 
The rationale for this approach is related to the hypothesis 
that in some cases of MN resistant to anti-CD20 treatments 
autoantibodies are produced by long-lived memory plasma 
cells CD20 negative.
Proteasome inhibitor bortezomib induced complete 
remission in a nephrotic patient resistant to high-dose steroid 
treatment [90] and in a case of post-transplantation recur-
rent MN resistant to RTX [91]. The development of a sec-
ond generation of proteasome inhibitor, which presents a 
better safety profile with respect to bortezomib, could open 
new perspectives for the use of anti-plasma cell treatment in 
resistant MN. Another class of anti-plasma cell drugs with 
potential to be useful in MN treatment is represented by 
monoclonal antibodies, such as daratumumab or isatuximab, 
which target CD38, a multifunctional cell surface protein 
highly expressed by plasma cells but not in other blood cells 
or solid tissues [92].
The experience regarding the use of these new agents 
in MN treatment is still limited and, therefore, more data 
about their efficacy and safety is needed. New studies are 
necessary for a better understanding of the role that new 
anti-CD20 agents, belimumab and anti-plasma cells treat-
ment can play in resistant disease.
A serological approach to treatment
As discussed above, the traditional approach for the clini-
cal decision regarding immunosuppressive therapy has been 
based on the Toronto Risk Score [22]. The advantage of this 
model is that it only requires an assessment of kidney func-
tion and proteinuria, and the risk can be calculated repeat-
edly during the period of follow-up. The problem with this 
model is that that proteinuria and serum creatinine may not 
accurately reflect disease activity nor discriminate between 
immunologically active disease and irreversible structural 
glomerular damage. On the other hand, changes in anti-
PLA2R levels typically precede reduction of proteinuria by 
several months. In patients with high anti-PLA2R levels, 
the observation period required using the proteinuria model 
may delay treatment resulting in significant kidney damage.
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As such, an individualized serology-based approach that 
complements and refines the traditional proteinuria-driven 
approach has been recently proposed [8]. Patients with 
low or decreasing anti-PLA2R antibody levels are more 
likely to go into spontaneous remission and thus should be 
treated conservatively. On the other hand, high baseline or 
increasing anti-PLA2R antibody levels are associated with 
nephrotic syndrome and progressive loss of kidney function, 
favoring prompt initiation of immunosuppressive therapy. 
Monitoring serum anti-PLA2R antibody levels reliably pre-
dicts the response to therapy, and levels at completion of 
therapy may forecast the long-term outcome. Re-emergence 
of or increase in antibody titers precedes a clinical relapse.
The hope is that such an approach will improve prognos-
tic accuracy and provide for an individualized treatment of 
patients with PLA2R-associated MN while limiting unnec-
essary exposure to immunosuppressive therapy. An RCT 
comparing the serology-based with the traditional approach 
is needed to confirm that such an approach is valid and appli-
cable in clinical practice [8].
Conclusions
The discovery of anti PLA2R Ab has revolutionized our 
approach to MN. With some exceptions, we now have the 
tools to definitively identify an aspecific histological lesion 
with a specific etiology, limiting the previously wide grey 
zone called “idiopathic MN”. The availability of anti-
PLA2R Abs assays helps clinicians in the timing and moni-
toring of immunosuppressive therapy and in some selected 
cases could even allow to avoid renal biopsy, especially in 
cases of increased risk of complication.
Today, our therapeutic panel against primary MN has 
been enriched with RTX-based regimens which have been 
widely used in numerous case series and reports. Consist-
ent evidence in terms of efficacy and side effects has been 
published. Two RCTs still ongoing should further elucidate 
whether treatment with RTX is as effective as conventional 
therapies in inducing remission of proteinuria in patients 
with MN as well as in maintaining these patients in remis-
sion long-term, while showing a favorable side-effect profile.
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